14 results
Diuretic Electrolyte Excretion Effects 
Diuresis, Na+, K+, Mg2+, Ca2+, Cl-, HCO3-, Uric Acid
 - Thiazide Type
Diuretic Electrolyte ... Excretion Effects Diuresis ... +, Mg2+, Ca2+, Cl ... electrolytes #effects #pharmacology ... #comparison #table
IDSA Treatment of Necrotizing Infections of the Skin, Fascia, and Muscle
 • Mixed infections
 • Streptococcus
IDSA Treatment of ... fasciitis #Skin #IDSA ... #Treatment #management ... #antibiotics #pharmacology
Parenteral Antimicrobial Treatment of Common Microorganisms Causing Native Vertebral Osteomyelitis - IDSA 
Staphylococci, oxacillin susceptible
Staphylococci, oxacillin
Antimicrobial Treatment ... Osteomyelitis - IDSA ... Parenteral #IV #Antibiotics ... #pharmacology # ... idsa
Pharmacokinetics of commonly used diuretics medications in CKD, Cirrhotic Ascites, and Heart Failure
 • Furosemide
 •
commonly used diuretics ... Spironolactone MCW ... MCW_Nephrology #diuretics ... #pharmacology # ... Pharmacokinetics #halflife #comparison
Outpatient Treatment of with Community-Acquired Pneumonia (CAP)
No comorbidities or risk factors for MRSA or Pseudomonas aeruginosa:
Outpatient Treatment ... fluoroquinolone #IDSA ... Acquired #Pneumonia #Antibiotics ... #Treatment #Regimen ... Management #Guidelines #pharmacology
Diuretics and Agents Regulating Renal Excretion

Carbonic Anhydrase Inhibitors (Acetazolamide, Dichlorphenamide)
 • Glaucoma
 • Epilepsy
 • Altitude
Diuretics and Agents ... Inhibitors of Na+K+2Cl ... Symport (Loop Diuretics ... Tolvaptan) • Treatment ... #Nephrology #Pharmacology
IDSA 2017 CDiff Guidelines - Table 7. Potential Treatment Agents for Treatment of the Primary Clostridium difficile
IDSA 2017 CDiff ... Potential Treatment ... Agents for Treatment ... infection Episode #Pharmacology ... IDSA2017 #Adjunct #Antibiotics
Selected Oral Antibacterial Agents With Excellent Oral Bioavailability Commonly Used to Treat Patients With Native Vertebral
Osteomyelitis #Oral #Antibiotics ... Osteomyelitis #management #treatment ... #pharmacology # ... idsa
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
IDSA Recommendations ... 100 cells/mm3 g/mL ... Penicilliosis #IDSA ... #Prevention #Treatment ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
IDSA Recommendations ... suspension 4–6 mL ... for effective treatment ... candida #mucosal #IDSA ... infections #HIVAIDS #pharmacology